Literature DB >> 8216363

Aminoguanidine: a drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro.

P Ou1, S P Wolff.   

Abstract

Aminoguanidine (AG) has been proposed as a drug of potential benefit in prophylaxis of the complications of diabetes. We show here that AG irreversibly inhibits catalase with an efficacy similar to aminotriazole. AG also produces hydrogen peroxide, in a transition metal-catalysed process which may be partially dependent upon prior hydrolysis of AG to semicarbazide and hydrazine. These observations may be of importance in proposals for the long term administration of AG in diabetes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8216363     DOI: 10.1016/0006-2952(93)90461-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  21 in total

Review 1.  [Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus].

Authors:  P P Nawroth; A Bierhaus; G E Vogel; M A Hofmann; M Zumbach; P Wahl; R Ziegler
Journal:  Med Klin (Munich)       Date:  1999-01-15

2.  Formation of advanced glycation end (AGE) products in diabetes: prevention by pyruvate and alpha-keto glutarate.

Authors:  S D Varma; P S Devamanoharan; A H Ali
Journal:  Mol Cell Biochem       Date:  1997-06       Impact factor: 3.396

3.  Pacing-induced delayed protection against arrhythmias is attenuated by aminoguanidine, an inhibitor of nitric oxide synthase.

Authors:  A Kis; A Végh; J Papp; J Parratt
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

4.  Reactive oxygen species regulate oxygen-sensitive potassium flux in rainbow trout erythrocytes.

Authors:  A Y Bogdanova; M Nikinmaa
Journal:  J Gen Physiol       Date:  2001-02       Impact factor: 4.086

Review 5.  Nitric oxide synthases: structure, function and inhibition.

Authors:  W K Alderton; C E Cooper; R G Knowles
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

6.  Role of nitric oxide in the circulatory failure and organ injury in a rodent model of gram-positive shock.

Authors:  K M Kengatharan; S J De Kimpe; C Thiemermann
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

7.  Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock.

Authors:  C C Wu; S J Chen; C Szabó; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

8.  Aminosalicylic acid reduces the antiproliferative effect of hyperglycaemia, advanced glycation endproducts and glycated basic fibroblast growth factor in cultured bovine aortic endothelial cells: comparison with aminoguanidine.

Authors:  Yasotha Duraisamy; John Gaffney; Mark Slevin; Christopher A Smith; Kenneth Williamson; Nessar Ahmed
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

9.  Influence of aminoguanidine and the endothelin antagonist, SB 209670, on the regional haemodynamic effects of endotoxaemia in conscious rats.

Authors:  S M Gardiner; P A Kemp; J E March; T Bennett
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 10.  Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injury.

Authors:  Suzanne Heemskerk; Rosalinde Masereeuw; Frans G M Russel; Peter Pickkers
Journal:  Nat Rev Nephrol       Date:  2009-09-29       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.